Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Spinal Cord Compression. ICORG 05-03, V6

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00968643
Recruitment Status : Completed
First Posted : August 31, 2009
Last Update Posted : December 31, 2014
Sponsor:
Information provided by (Responsible Party):
Cancer Trials Ireland

Brief Summary:

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which radiation therapy schedule is more effective in treating patients with malignant spinal cord compression.

PURPOSE: This randomized phase III trial is studying two different radiation therapy schedules to compare their side effects and how well they work in treating patients with malignant spinal cord compression.


Condition or disease Intervention/treatment Phase
Spinal Cord Compression Unspecified Adult Solid Tumor, Protocol Specific Radiation: radiation therapy Phase 3

Detailed Description:

OBJECTIVES:

Primary

  • To compare the response in patients with malignant spinal cord compression treated with single fraction (10 Gy) radiotherapy vs standard multiple fraction (20 Gy) radiotherapy.
  • To compare the toxicity of these treatment regimens in these patients.

Secondary

  • Examine the safety, practicability, and efficacy of treatment with a single 10 Gy fraction of radiotherapy in these patients.
  • Analyze the initial neurological status, document the response to treatment, and calculate median survival of these patients.
  • Perform an economic impact analysis comparing the two treatment arms.

OUTLINE: This is a multicenter study. Patients are stratified according to participating center. Patients are randomized to 1 of 2 treatment arms.

  • Arm I (control): Patients undergo radiotherapy to the area of spinal cord compression once daily for 5 days (total of 20 Gy).
  • Arm II: Patients undergo a single fraction of radiotherapy to the area of spinal cord compression (total of 10 Gy).

Patients complete the EORTC QLQ-C30 quality-of-life questionnaire at baseline, at 5 weeks, and then every 3 months thereafter.

After completion of study treatment, patients are followed up at 1 and 5 weeks, at 3 months, and then every 3 months thereafter.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 126 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised Phase III Trial of Two Fractionation Schemes in the Treatment of Malignant Spinal Cord Compression
Study Start Date : January 2006
Actual Primary Completion Date : May 2014

Arm Intervention/treatment
Active Comparator: Arm I (control)
Patients undergo radiotherapy to the area of spinal cord compression once daily for 5 days (total of 20 Gy).
Radiation: radiation therapy
Given in multiple fractions or as a single fraction

Experimental: Arm II
Patients undergo a single fraction of radiotherapy to the area of spinal cord compression (total of 10 Gy).
Radiation: radiation therapy
Given in multiple fractions or as a single fraction




Primary Outcome Measures :
  1. Mobility status: measured by the change in mobility status between baseline and 5 weeks, as measured by the in-house mobility scale [ Time Frame: 5 weeks from date of randomisation ]

Secondary Outcome Measures :
  1. Quality of life as assessed by the EORTC QLQ-C30 version 3 quality-of-life questionnaire [ Time Frame: 5 weeks from date of randomisation ]
  2. Toxicity: assessed at first follow-up, evaluated as per standard RTOG acute and long-term toxicity scale [ Time Frame: 1 week after completion of therapy ]
  3. Pain control: assessed using a Visual Analogue Scale [ Time Frame: Until death ]
  4. Overall survival: the survival duration will be calculated from time of randomisation to death whatever cause [ Time Frame: Until death ]
  5. Sphincter function: assessed using an 'In-House' Bladder Function Scale [ Time Frame: Until death ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed malignancy, excluding the following:

    • Leukemia
    • Myeloma
    • Germ cell tumor
    • Primary tumor of the spine or vertebral column
  • Diagnosis of malignant spinal cord compression confirmed by MRI of the entire spine
  • Deemed inoperable or unsuitable for neurosurgical intervention at the time of initial assessment
  • No single bone metastasis with controlled primary site

PATIENT CHARACTERISTICS:

  • Karnofsky performance status 30-100%
  • No medical or psychiatric condition that, in the opinion of the investigator or research team, would contraindicate study participation

PRIOR CONCURRENT THERAPY:

  • No prior radiotherapy to the involved area of the spinal cord such that further treatment exceeds spinal cord tolerance

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00968643


Locations
Layout table for location information
Ireland
Cork University Hospital
Cork, Ireland
Saint Luke's Radiation Oncology Network (SLRON)
Dublin, Ireland, 6
Galway University Hospital
Galway, Ireland
Whitfield Cancer Centre at Whitfield Clinic
Waterford, Ireland
Sponsors and Collaborators
Cancer Trials Ireland
Investigators
Layout table for investigator information
Principal Investigator: Pierre Thirion St Luke's Radiation Oncology Network

Layout table for additonal information
Responsible Party: Cancer Trials Ireland
ClinicalTrials.gov Identifier: NCT00968643     History of Changes
Other Study ID Numbers: 05-03 ICORG
ICORG-05-03
EU-20952
First Posted: August 31, 2009    Key Record Dates
Last Update Posted: December 31, 2014
Last Verified: August 2014
Keywords provided by Cancer Trials Ireland:
spinal cord compression
unspecified adult solid tumor, protocol specific
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Cord Compression
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Spinal Cord Injuries
Wounds and Injuries